Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Current Liabilities (2016 - 2025)

Seres Therapeutics' Total Current Liabilities history spans 11 years, with the latest figure at $22.4 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 65.4% year-over-year to $22.4 million; the TTM value through Sep 2025 reached $22.4 million, down 65.4%, while the annual FY2024 figure was $41.2 million, 58.22% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $22.4 million at Seres Therapeutics, down from $30.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $108.3 million in Q2 2024 and bottomed at $22.4 million in Q3 2025.
  • The 5-year median for Total Current Liabilities is $79.2 million (2023), against an average of $70.4 million.
  • The largest annual shift saw Total Current Liabilities skyrocketed 106.67% in 2021 before it crashed 71.43% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $82.3 million in 2021, then increased by 4.06% to $85.6 million in 2022, then rose by 15.26% to $98.7 million in 2023, then plummeted by 58.22% to $41.2 million in 2024, then crashed by 45.59% to $22.4 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Total Current Liabilities are $22.4 million (Q3 2025), $30.9 million (Q2 2025), and $31.3 million (Q1 2025).